Group 1 - The core viewpoint of the news highlights the performance of the TaiKang Medical Health Fund, which saw declines in its two share classes, with Class C down by 13.45% and Class A down by 13.02% in 2025 [2][3] - The top ten holdings of the TaiKang Medical Health Fund in the third quarter of 2025 included companies such as JingTai Holdings, Kanglong Chemical, Fangzhou Jianke, SanSheng Pharmaceutical, Zhaoyan New Drug, Jiuan Medical, Yirui Technology, Lingrui Pharmaceutical, Baipusais, and Bid Medical [2] - The fund manager, Fu Hongzhe, has a background as a senior researcher at China Europe Fund Management Co., and has been with TaiKang since July 2019, becoming the fund manager on March 8, 2022 [2]

（文章来源：证券日报） 证券日报网讯 1月13日，昭衍新药在互动平台回答投资者提问时表示，公司非人灵长类模型主要是自 用，用于非临床安评实验相关研究，不涉及脑机接口业务，相关信息请以公司披露的相关公告为准。 ...

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

格隆汇1月13日丨昭衍新药(603127.SH)在互动平台表示，公司非人灵长类模型主要是自用，用于非临床 安评实验相关研究，不涉及脑机接口业务。 ...

格隆汇1月13日丨昭衍新药(603127.SH)在互动平台表示，公司非人灵长类模型主要是自用，用于非临床 安评实验相关研究，不涉及脑机接口业务。 ...

Core Insights - The medical services sector experienced a significant increase of 4.15% on January 13, with Norska leading the gains [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Group 1: Stock Performance - Norska (301333) closed at 76.48, up 20.01% with a trading volume of 55,200 shares and a transaction value of 397 million yuan [1] - Yingsi (301257) also saw a rise of 20.00%, closing at 72.24 with a trading volume of 22,900 shares [1] - Hongbo Pharmaceutical (301230) increased by 20.00%, closing at 56.64 with a trading volume of 57,200 shares [1] - Lanwei Medical (301060) rose by 19.96%, closing at 13.28 with a trading volume of 135,210 shares [1] - Boji Pharmaceutical (300404) increased by 19.96%, closing at 12.92 with a trading volume of 627,100 shares [1] - Dian Diagnostics (300244) saw an increase of 11.90%, closing at 29.16 with a trading volume of 1,516,000 shares [1] Group 2: Capital Flow - The medical services sector saw a net inflow of 1.497 billion yuan from institutional investors, while retail investors experienced a net outflow of 713 million yuan [2] - The main stocks with significant capital flow include International Medical (000516) with a net inflow of 259 million yuan from institutional investors [3] - Boji Pharmaceutical (300404) had a net inflow of 243 million yuan from institutional investors, but also saw a net outflow of 140 million yuan from retail investors [3]

Group 1 - The core viewpoint of the news is that the Taikang Medical Health Fund has experienced significant declines in its stock performance for both Class C and Class A shares, with decreases of 13.45% and 13.02% respectively in 2025 [1][2] - The top ten holdings of the fund as of the third quarter of 2025 include companies such as Jingtai Holdings, Kanglong Chemical, Fangzhou Jianke, Sanofi Pharmaceutical, Zhaoyan New Drug, Jiuan Medical, Yirui Technology, Lingrui Pharmaceutical, Baipusais, and Bid Medical [1] - The fund manager, Fu Hongzhe, has a background as a senior researcher at China Europe Fund Management Co., Ltd. and has been with Taikang since July 2019, becoming the fund manager on March 8, 2022 [1]

Core Insights - The Chinese healthcare industry has undergone a significant transformation from 2020 to 2025, transitioning from a "golden era" of investment to a "bubble-clearing period" characterized by a K-shaped divergence in market performance [1][2][4]. Group 1: K-shaped Downward Trends - The collapse of previously successful business models, particularly in CXO, consumer healthcare, and internet healthcare, has led to substantial market value losses, with some companies experiencing declines of over 90% [4][7]. - The downturn is attributed to macroeconomic factors such as U.S. interest rate hikes and geopolitical tensions, as well as microeconomic issues like supply-demand imbalances and the disappearance of growth dividends [8][10]. - The CXO sector, once seen as a perpetual growth engine, has faced a 46.68% decline for WuXi Biologics and 44.47% for Tigermed, revealing the fragility of its business model reliant on continuous global financing [12][10]. - Consumer healthcare has suffered a "Davis double whammy," with companies like Yonghe Medical and Aier Eye Hospital seeing declines of 86.19% and 52.69%, respectively, as consumer spending shifts away from discretionary healthcare services [14][15]. - Internet healthcare companies, including Zhiyun Health and Dingdang Health, have also faced severe declines, with drops of 92.44% and 90.67%, as the market realizes that their revenue largely comes from online drug sales rather than innovative healthcare solutions [19][21]. Group 2: K-shaped Upward Trends - In contrast, companies with strong global rights and hard-core technology have thrived, with Keren Biotechnology and Kangfang Biopharma seeing increases of 518.33% and 166.72%, respectively, marking a shift towards biopharma and global market engagement [29][31]. - The rise of these companies signifies a new era where capital is attracted to firms that can demonstrate robust clinical data and global market potential, moving away from mere concepts [30][31]. - Even within struggling sectors, some companies like WuXi AppTec and Yuyue Medical have shown resilience, with increases of 113.36% and 28.75%, respectively, by focusing on high-tech, high-barrier services [34][35]. Group 3: Challenges Ahead - Despite the emergence of new leaders, significant challenges remain, including the risks associated with licensing agreements that may compromise long-term profitability [36][37]. - The ADC sector is experiencing a rush similar to the past PD-1 craze, raising concerns about market saturation and price competition, which could undermine future profitability [39][40]. - The ongoing "ice age" in the primary market poses a threat to innovation, as funding for early-stage companies has become increasingly scarce, potentially leading to a decline in new drug approvals in the coming years [42][43].

1月13日，昭衍新药涨5.1%，截至发稿，报42.44元/股，成交5.77亿元，换手率2.19%，总市值318.02亿 元。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，融通基金旗下1只基金重仓昭衍新药。融通医疗保健行业混合A/B（161616）三季度减持 31.85万股，持有股数93.83万股，占基金净值比例为3.95%，位居第六大重仓股。根据测算，今日浮盈 赚取约193.3万元。 融通医疗保健行业混合A/B（161616）成立日期2012年7月26日，最新规模7.08亿。今年以来收益 8.55%，同类排名1381/8836；近一年收益22.93%，同类排名5278/8091；成立以来收益143.83%。 融通医疗保健行业混合A/B（161616）基金经理为万民远、刘曦阳。 截至发稿，万民远累计任职时间9年143天，现任基金资产总规模59.57亿元，任职期间最佳基金回报 149.74%， 任职期间最差基金回报-19.05%。 刘曦阳累计 ...

资金流向方面，Wind数据显示，该ETF近5个交易日连续获资金净流入，累计"吸金"近9亿元。 创新药ETF（159992）紧密跟踪中证创新药产业指数。该指数选取主营业务涉及创新药研发的上市公司 作为待选样本，按照市值排序选取不超过50家最具代表性公司作为样本股，以反映创新药产业上市公司 的整体表现，为投资者提供新的投资标的。 1月13日，A股创新药板块盘初持续走强。 热门ETF中，创新药ETF（159992）持续拉升，截至发稿涨超2%，成交额超2亿元，交投活跃。 成分股中，荣昌生物涨超16%，泰格医药涨超6%，药明康德涨超5%，安科生物、康龙化成、昭衍新 药、三生国健等股涨幅居前。 此外，1月12日，药明康德(603259.SH)发布2025年度业绩预告，预计归属于上市公司股东的净利润为 191.51亿元，同比增长约102.65%。 国信证券表示，关注JPM年会及创新药在海外的临床进展。中国创新药产业已经体现出长期向好的发展 趋势，并在近年集中体现在BD交易的爆发式增长。值得注意的是，对于大部分国产创新药，对外授权 通常只是全球开发的起点，合作伙伴在海外的开发进度，以及后续全球临床数据的读出可以进一步加强 产 ...